MXPA06004674A

MXPA06004674A - Triazole compounds and uses related thereto

Info

Publication number: MXPA06004674A
Application number: MXPA/A/2006/004674A
Authority: MX
Inventors: G Cardozo Mario; P Powers Jay; Goto Hiroyuki; Harada Kazuhito; Imamura Katsuaki; Kakutani Makoto; Matsuda Isamu; Ohe Yasuhiro; Yata Shinji; Tu Hua
Original assignee: Amgen Sf Llc; G Cardozo Mario; Goto Hiroyuki; Harada Kazuhito; Imamura Katsuaki; Japan Tobacco Inc; Kakutani Makoto; Matsuda Isamu; Ohe Yasuhiro; P Powers Jay; Yata Shinji
Priority date: 2003-10-28
Filing date: 2006-04-26
Publication date: 2007-04-20

Abstract

The present invention provides a triazole compound of the following formula:a prodrug thereof or a pharmaceutically acceptable salt thereof. The above-mentioned triazole compound is useful as a therapeutic drug for the treatment of diabetes, obesity or metabolic syndrome.

Description

TRIAZOL COMPOUNDS AND USES RELATED TO THEM FIELD OF THE INVENTION The present invention relates to triazole compounds useful for, for example, the treatment or prophylaxis of diabetes, obesity and metabolic syndrome.

BACKGROUND OF THE INVENTION 11-beta-hydroxysteroid dehydrogenase 1 (hereinafter, "11-beta-HSD1" or "HSD1") catalyzes the interconversion of glucocorticoids (hereinafter "GC") between the inert 11-keto forms (e.g., cortisone, 11-dehydrocorticosterone) and active 11-beta-hydroxy forms (e.g., cortisol, corticosterone, respectively). The enzyme, in vivo, prefers the direction of reductase from 11-keto to 11-beta-hydroxy, in other words, the production of active GC. 11-beta-HSDl is expressed ubiquitously, most notably in liver, lung, adipose tissue, vasculature, ovaries and the central nervous system. Until recently, experimental results have suggested that the active form of GC produced through HSDl as well as the enzyme itself are implicated in various biological actions and diseases. For example, it is known that active GC stimulates gluconeogenic enzymes and has effects at least in part to induce hyperglycemia. In this situation, HSD1 can be a second source of GC production in addition to the adrenal glands. As another example, the continuous excess of active GC in peripheral tissues, such as that seen in Cushing's syndrome, leads to insulin resistance, in which HSDl is considered to have an important function. In addition, in the adipose tissue, it is shown that the Active GC increases the differentiation of pre-adipocytes to adipocytes. Mature adipocytes express HSD1 activity, which causes an increase in the local concentration of the active form and also the expansion of adipose tissue. This action of HSD1 must be critical in the pathogenesis of obesity. In addition, a local immuno-suppressive effect of HSD1 on deciduous placental membranes is suggested, and a relationship between the expression of the enzyme in the adrenal cortex and the induction of adrenaline synthesis. (To the above reference is made in: Quinkler M, Oelkers W &Díederich S (2001) European Journal of Endocrinology Vol. 144, pp. 87-97; and Seckl JR &Walker BR (2001) Endocrinology Vol. 142, pp. 1371-1376). In accordance with the above suggestions, it is expected that drugs that have inhibitory effects against HSD1 may be useful to treat or prevent diabetes mellitus, obesity, metabolic syndrome in connection with any of said diseases, or any other diseases that arise due to the HSD1 shares. Diabetes mellitus, a disease whose main characteristic is chronic hyperglycemia, introduces several metabolic abnormalities and presents symptoms of thirst, polydipsia, polyuria, etc. based on high glucose concentration. The continuous hyperglycemic state can also lead to diabetic complications such as retinopathy, nephropathy, neuropathy, and myocardial and / or cerebral infarction due to arteriosclerosis. In the treatment of diabetes, the moderate suppression of hyperglycemia is critical so that the onset and progress of complications can be suppressed. For these purposes, diets, ergotherapy and pharmacotherapy are used in combination on an appropriate basis and, among pharmacotherapy, many different strategies have been tried in mechanisms of action. Despite these various existing methods, sufficient therapeutic effect is not yet achieved.

Obesity is defined as a state of fatness that coincides with any disease that could improve or not progress in the case of weight reduction (eg diabetes, hyperlipidemia, hypertension) or with an excessive amount of fat in the viscera. It is considered that, in case that state persists, there may be at least two diabetes, hyperlipidemia, hypertension and etc., and the onset of infarction to the myocardium and / or the brain due to arteriosclerosis may occur. The main therapeutic methods to treat obesity are diet and ergotherapy, and it is subject to pharmacotherapy only if necessary, for example, due to the difficulty in the first two alternatives. However, existing drugs have several problems in terms of adverse effects and uses, because most of these suppress food mainly through central action. Consequently, until now, the development of any drug to treat diabetes and / or obesity with a novel mechanism of action is required. Under these circumstances, it is expected that drugs that have inhibitory effects against HSD1 may be useful as another alternative with separate ecanstic strategy to treat diabetes mellitus, as well as a novel class that "acts on adipose tissue" among other anti-obesity drugs.

As developing drugs for treating diabetes and / or obesity through the inhibition of HSD1, for example, WO 03/065983 discloses triazole compounds of the following general formula: [wherein: R1 is unsubstituted or substituted adamantyl; W is -N (Ra) - or an individual link; X is -CH2- or an individual bond; Z is -S- or an individual bond; Ra is -H or C ?_6 alkyl unsubstituted or substituted by one to five fluorine atoms; R2 is -H, unsubstituted or substituted Ci-io alkyl, unsubstituted or substituted C2_10 alkenyl, -CH2C02H, -CH2C02-C6_6 alkyl, -CH2CONHRa, - (CH2) or -3-cycloalkyl of C3_g ( optionally having double bonds, and may be unsubstituted or substituted), - (CH2) 0-2-bicycloalkyl of Cs_? 2 (optionally having double bonds, and may be unsubstituted or substituted), - (CH2) or- 2-adamantyl (either unsubstituted or substituted) or - (CH2) 0_2R; R3 is -H, unsubstituted or substituted C? ~? 0 alkyl, C2-? Alkenyl or unsubstituted or substituted, -Y-C3_9 cycloalkyl (optionally having double bonds, and may be unsubstituted or substituted), -Y-bicycloalkyl of C5_? 2 (optionally having double bonds, and may be unsubstituted or substituted), -Y-adamantyl (either unsubstituted or substituted) or YR; R is benzodioxolane, furan, tetrahydrofuran, thiophene, tetrahydrothiophene, dihydropyran, tetrahydropyran, pyridine, piperidine, benzofuran, dihydro-benzofuran, benzothiophene, dihydrobenzothiophene, indole, dihydroindole, indene, indane, 1,3-dioxolane, 1,3-dioxane, phenyl or naphthyl (any of said R unsubstituted or substituted); and Y is - (CH2) o-2- or (-HC = CH-)]. However, any description according to said request does not describe or make reference to any of the compounds having the structure of the present invention. The compounds of the present invention improve the physical chemical (stability, etc.) and biological profiles (activity to inhibit HSD1, specificity, bioavailability, metabolism, etc.), as a result of the selection of structural features as described herein. invention.

SUMMARY OF THE INVENTION In accordance with the present invention, it has been found that the triazole compounds represented by the following formula have superior HSD1 inhibitory activity, and are useful as inhibitors of HSD1 or therapeutic drugs for diabetes or obesity. The present invention provides the following. (1) A triazole compound represented by the following formula: wherein R1 is an alkyl group or a cycloalkyl group in which the alkyl group and the cycloalkyl group are optionally substituted with 1 to 5 substituents each independently selected from a halogen atom, -CF3, - OH, -NH2, an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N (R7) (R8), -N (R7) -CO-R8, a group aryl and a heteroaryl group in which R7 and R8 are each independently a hydrogen atom or an alkyl group, and the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents which are each independently selected from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group , -CO-R11, an aryl group and a heteroaryl group in which n is 0-3, R9 and R10 are each independently a hydrogen atom, or n alkyl or -CO-alkyl group, and R11 is -OH, an alkoxy group, an alkyl group or -N (R12) (R13) in which R12 and R13 are each independently a hydrogen atom or a group I rent; Y is a cycloalkyl group or a heterocycloalkyl group in which the cycloalkyl group and the heterocycloalkyl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom, a halogenoalkyl group, an alkyl group , - (CH) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group (n , R9, R10 and R11 are as defined above); Ar1 is an aryl group or a heteroaryl group; R2 and R3 are each independently a hydrogen atom, a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group or a heteroaryl group in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents each of which are independently selected from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group , -CO-R11, an aryl group and a heteroaryl group (n, R9, R10 and R11 are as defined above); Z is - (CH (R14)) p-, - (CH (R14)) p-N (R16) - (CH (R15)) q- or wherein Y x is a cycloalkyl group or a heterocycloalkyl group in which the cycloalkyl group and the heterocycloalkyl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a group heteroaryl (n, R9, R10 and R11 are as defined above), ?? "p is 0-3, q is 0-3, R14 and R15 are each independently a hydrogen atom, a halogen atom, a halogenoalkyl group, an alkyl group, (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group or a heteroaryl group in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents which are each independently selected at par of a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group (n, R9, R10 and R11 are as defined above), and R16 is a hydrogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH , - (CH2) n-C0-R1: L, a cycloalkyl group, an alkenyl group, an aryl group or a heteroaryl group in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents which are selected each one independently from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n ~ 0H, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group , an alkenyl group, -CO-R11, an aryl group and a heteroaryl group (n, R9, R10 and R11 are as defined above); Ar2 is an aryl group, a heteroaryl group or in which Xi is - (CH2) t- in which t is 0-2, Vi is = CH- or = N-, and Wi is -C (R17) (R18) -, -O-, -S- , -S02-, -SO-, -CO- or -N (R19) - in which R17 and R18 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a halogenoalkyl group, - ( CH2) r-OH, -CO-R20, -N (R21) (R22) or -Li-Ar3 in which r is 0-3, R20 is -OH, an alkoxy group, an alkoxyalkyl group or -N (R23) ) (R24) in which R23 and R24 are each independently a hydrogen atom, an alkyl group, - (CH2) s-0H, an alkoxyalkyl group, or in combination form wherein s is 0-3, X2 is -O-, - (CH2) t- or -N (R25) ~ in which t is as defined above and R25 is a hydrogen atom, -CO-R26, -S02-R26 or - (CH2) U-Ar4 in which R26 is an alkyl group, an alkoxy group, -NH-alkyl or -N (-alkyl) 2,? U "is 0-3, and Ar4 is an aryl group or a heteroaryl group in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-0H, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group (n, R9) , R10 and R11 are as defined above), Li is - (CH2) V-, -O- or -CO- in which v is 0-3, and Ar3 is an aryl group or a heteroaryl group in which the The aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents which are each independently selected of a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, a group alkenyl, -CO-R11, an aryl group and a heteroaryl group (n, R9, R10 and R11 are as defined above), and R21 and R22 are each independently a hydrogen atom, an alkyl group, -CO -alkyl, -CO-0-alkyl or -L? -Ar3 (Li and Ar3 are as defined above), and R19 is a hydrogen atom, -CO-R26, -S02-R26 or - (CH2) U- Ar4 (R26, "u" and Ar4 are as defined above); and R4 and R5 are each independently a hydrogen atom, a halogen atom, -OH, -N02, -CN, an alkyl group, an alkoxy group, -CO-R27, -S02-R27, -C0- N (R28) (R29) or -N (R30) (R31) in which the alkyl group and the alkoxy group are optionally substituted with 1 to 5 substituents each independently selected from a halogen atom, -CF3, -OH, an alkoxy group, a halogenoalkoxy group, -N (R9) (R10), -CN, -N02, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group ( R9, R10 and R11 are as defined above), in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n_OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a het group eroaryl (n, R9, R10 and R11 are as defined above) R27 is -OH, an alkoxy group, an alkyl group, -NH2, -NH-alkyl or - (-alkyl) 2, R28 and R29 are each independently a hydrogen atom, an alkyl group or - (CH2) W-R32, in which w is 0-3 and R is -OH, -CF3, an alkoxy group, -CONH2 or -N (R33) (R34) ) in which R33 and R34 are each independently a hydrogen atom, an alkyl group, -CO-alkyl, or in combination form / \ • N X, \ / " (X2 is as defined above) or R28 and R29 in combination form where X3 is -CO-, -CH2- or -CH2-CH2-, X is -O-, - (CH2) t-, -N (R 2"5,) or wherein Y2 is cycloalkyl or heterocycloalkyl and "t" and R25 are as defined above, and R35 and R36 are each independently a hydrogen atom, a halogen atom, an alkyl group optionally substituted with -OH, - OH, -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R37, -N (R38) (R39) in which R37 is -OH, an alkoxy group, -NH2, -NHalkyl , ~ N (-alkyl) 2 or N X, (X2 is as defined above) in which the alkyl group in -NH-alkyl and -N (-alkyl) 2 and the alkoxy group are optionally substituted with 1 to 5 substituents which are each independently selected from a halogen atom, -CF3, -OH, an alkoxy group, a halogenoalkoxy group, -N (R9) (R10), -CN, -N02, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group (R, R and R are as defined above), in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom , a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, a aryl group and a heteroaryl group (n, R9, R10 and R11 are as defined above), and R38 and R39 are each independently a hydrogen atom, or n alkyl group, -CO-alkyl or -C0-0-alkyl, and R30 and R31 are each independently a hydrogen atom, an alkyl group optionally substituted with -OH, -S02-R40, - (CH2) x -C0-R41 or wherein x is 0-3, R40 is an alkyl group or -NH2, R41 is a hydrogen atom, an alkyl group optionally substituted with -OH, -OH, an alkoxy group, an alkoxyalkyl group or - (CH2) S - N (R42) (R43) in which "s" is as defined above and R42 and R43 are each independently a hydrogen atom, an alkyl group, -OH, an alkoxy group, or in combination form (X3, X, R35 and R36 are as defined above), V2 is = CH- or = N- and W2 is -C (R44) (R45) -, -0- or -N (R46) - in which R44 and R45 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a halogenoalkyl group, - (CH2) r-0H, -CO-R47 or -N (R48) (R49) in which r is as defined above, R47 is -OH, an alkoxy group, an alkoxyalkyl group, N (R5Q) (R51) in which R50 and R51 are each independently a hydrogen atom, an alkyl group, - (CH2) s-OH ("s" is as defined above) or an alkoxyalkyl group, and R48 and R49 are each independently a hydrogen atom, an alkyl group, -CO-alkyl or -CO-0 -alkyl, and R46 is a hydrogen atom, -CO-R52 or -S02-R52 in which R52 is an alkyl group, an alkoxy group, -NH-alkyl or -N (-alkyl) 2 or R30 and R31 in combination form (X3, X4, R35 and R36 are as defined above), or R4 and R5 in combination can form -O-alkylene-O-, a prodrug thereof or a pharmaceutically acceptable salt thereof. (2) The triazole compound of (1) above, in which Z is - (CH (R1)) p- and p is 0, a prodrug thereof or a pharmaceutically acceptable salt thereof. (3) The triazole compound of (2) above, in which Y is a C3-8 cycloalkyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof. (4) The triazole compound of (3) above, in which Ar1 is a phenyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof. (5) The triazole compound of (4) above, wherein R 2 and R 3 are each independently a halogen atom or a hydrogen atom, a prodrug thereof or a pharmaceutically acceptable salt thereof. (6) The triazole compound of any of (1) to (5) above, in which Ar2 is a phenyl group, R4 is a hydrogen atom, a halogen atom or an alkoxy group and R5 is -CO-N (R28) (R29), a prodrug thereof or a pharmaceutically acceptable salt thereof . (7) The triazole compound of (6) above, wherein R28 and R29 are each independently a hydrogen atom or an alkyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof. (8) The triazole compound of any of (1) to (5) above, in which Ar is a phenyl group, R is a hydrogen atom or a halogen atom and R5 is -N (R30) (R31) wherein R30 is a hydrogen atom and R31 is - (CH2) x-CO-R41, a prodrug thereof or a pharmaceutically acceptable salt thereof. (9) The triazole compound of (8) above, wherein X is 0 and R41 is an alkoxy group, a prodrug thereof or a pharmaceutically acceptable salt thereof. (10) The triazole compound of (8) above, wherein X is 0 and R41 is - (CH2) S-N (R42) (R43), a prodrug thereof or a pharmaceutically acceptable salt thereof. (11) The triazole compound of (10) above, in which "s" is 0, R42 is a hydrogen atom and R43 is an alkoxy group, a prodrug thereof or a pharmaceutically acceptable salt thereof. (12) The triazole compound of any of (1) to (5) above, in which Ar2 is a phenyl group, R4 is a hydrogen atom and R5 is -N (R30) (R31) in which R30 and R31 join to form and X3 is -CO-, a prodrug thereof or a pharmaceutically acceptable salt thereof. (13) The triazole compound of (12) above, wherein X is -O-, a prodrug thereof or a pharmaceutically acceptable salt thereof. (14) The triazole compound of (1) above, which is 3-chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4H- [1,2, 4] triazole-3- il] -benzamide,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzoyl} morpholine, 3-chloro-N-methyl-4- [4-methyl-5- (1-phenyl-cyclo-propyl) -4H- [1,2, 4] triazol-3-yl] -benzamide, 3-chloro-N, N-dimethyl-4- [4-methyl-5- (1-phenyl-cyclo-propyl) -4H- [1,2, 4] triazol-3-yl] -benzamide, 3-chloro-N- (2-hydroxy-ethyl) ) -4- [4-methyl-5- (1-phenyl-cyclopropyl) -4 H- [1,2-] triazol-3-yl] benzamide, 3-chloro-N-isopropyl-4- [4-methyl- 5- (1-phenylcyclopropyl) -4H- [1,2,] triazol-3-yl] benzamide,. { 3-Chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4H [1,2,] triazol-3-yl] benzoyl} piperidine,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H [1,2, 4] triazol-3-yl] benzoyl} - (4-hydroxy) piperidine, N-carbamoylmethyl-3-chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4 H- [1, 2,4] triazol-3-yl] benzamide, 3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] -N- (2,2,2-trifluoro-ethyl) -benzamide , N ~ (2-acetylamino) ethyl-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] benzamide, 3-chloro- N- (2-methoxy) -ethyl-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzamide, 1-acetyl- (4- {3-Chloro-4- [4-methyl-5- (1-phenyl-cyclo-propyl) -4H- [1,2, 4] triazol-3-yl] -benzoyl}. Piperazine, 3-chloro-N- (2-dimethylamino) ethyl-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] benzamide, 3-chloro-4- [4-methyl- 5- (1-phenylcyclopropyl) -4H- [1, 2,4] triazol-3-yl] -N- (2-morpholin-4-yl) ethylbenzamide, 4- [4-methyl-5- (1-phenylcyclopropyl) ) -4H- [1,2, 4] triazol-3-yl] -3-methoxybenzamide, 3-chloro-4-. {4-methyl-5- [1- (4-fluorophenyl) cyclopropyl] -4H- [1,2,4] triazol-3-yl.} Benzamide, 3-chloro-N-methyl-4-. methyl-5- [1- (4-fluorophenyl) -cyclopropyl] -4H- [1,2,4] triazol-3-yl} benzamide, 4- [4-isopropyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] benzamide, 4-. { 5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,2, 4] triazol-3-yl} benzamide, 4-chloro-3-. { 5- [1- (4-fluorophenyl) cyclopropyl] -4-methyl-4H- [1,2, 4] triazol-3-yl} benzamide, 4-chloro-3-. { 5- [1-phenylcyclopropyl] -4-methyl-4H- [1,2, 4] triazol-3-yl} benzamide, 3-chloro-4- [4-ethyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzamide, 3-chloro-4. { 4-ethyl-5- [1- (4-fluorophenyl) cyclopropyl] -4H- [1,2,] triazol-3-yl} benzamide, 3- [4-isopropyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] -triazol-3-yl] benzamide, 3-. { 5- [1- (4-Fluoro-phenyl) -cyclopropyl] -4-isopropyl-4H- [1,2,4] triazol-3-yl} benzamide, N-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} -l-morpholinecarboxamide, 3-. { 3-Chloro-4- [4-methyl-5 - '(1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] -phenyl} -l, 1-dimethylurea,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] -phenyl} urea, N-. { 3-Chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -phenyl} ethyl carbamate, N- [3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} -l- (4-methoxypiperidine) -carboxamide, N-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] phenyl} -l- (3-hydroxypiperidine) -carboxamide, N-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} -l- (4-hydroxypiperidine) -carboxamide, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -phenyl} -3-methoxyurea, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} -3-hydroxy-3-methylurea, 1- (3-chloro-4-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-methyl-4H- [1,2,4] triazole-3 -yl.}. phenyl) -3-methoxyurea, 1- (4-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1, 2, 4] triazole-3- il.) phenyl) -3-methoxyurea, 1- (3. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1, 2,4] triazol-3-yl} phenyl) -3-methoxyurea, 3-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -phenyl} oxazolidin-2-one, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] phenyl} Imidazolidin-2-one, 3- (3-chloro-4-5- [1- (4-fluoro-phenyl) -cyclopropyl] -4-methyl-4H- [1, 2, 4] triazol-3-yl. phenyl) oxazolidin-2-one, 3- (4-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,2, 4] triazol-3-yl. phenyl) oxazolidin-2-one, 3- (4-chloro-3-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-methyl-4H- [1,2,4] triazole- 3-yl.} Phenyl) oxazolidin-2-one, 3- (3. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,2,] triazole-3 -yl.}. phenyl) oxazolidin-2-one, N- (4-chloro-3-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-methyl-4H- [1, 2, 4 methyl triazol-3-yl.} phenyl) carbamate, a prodrug thereof or a pharmaceutically acceptable salt thereof. (15) The triazole compound of (1) above, which is 3-chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4H- [1,2,4] triazole-3- il] -benzamide,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzoyl} morpholine, 3-chloro-N-methyl-4- [4-methyl-5- (1-phenyl-cyclo-propyl) -4H- [1,2, 4] triazol-3-yl] -benzamide, 3-chloro-N, N-dimethyl-4- [4-methyl-5- (1-phenyl-cyclo-propyl) -4H- [1,2, 4] triazol-3-yl] -benzamide, 3-chloro-N- (2-hydroxy-ethyl) ) -4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] -benzamide, 3-chloro-N-isopropyl-4- [4-methyl- 5- (1-Phenyl-cyclo-propyl) -4H- [1, 2,4] triazol-3-yl] benzamide,. { 3-Chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzoyl} piperidine,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzoyl} - (4-hydroxy) piperidine, N-carbamoylmethyl-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2,] triazol-3-yl] benzamide, 3-chloro -4- [4-Methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] -N- (2,2,2-trifluoroethyl) -benzamide, N- (2 -acetylamino) ethyl-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] benzamide, 3-chloro-N- (2- methoxy) ethyl-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4 H- [1, 2, 4] triazol-3-yl] benzamide, 1-acetyl- (4-. {3- chloro-4- [4-methyl-5- (1-phenyl-cyclo-propyl) -4H- [1,2,4] triazol-3-yl] benzoyl.} piperazine, 3-chloro-N- (2-dimethylamino) ) ethyl-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] benzamide, 3-chloro-4- [4-methyl-5- (1 phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] -N- (2-morpholin-4-yl) -ethylbenzamide, 4- [4-methyl-5- (1-phenylcyclopropyl) -4H - [1,2, 4] triazol-3-yl] -3-methoxybenzamide, 3-chloro-4-. {4-methyl-5- [1- (4-fluorophenyl) cyclopropyl] -4H- [1, 2,4] triazol-3-yl.}. Benzamide, 3-chloro-N-methyl-4- { 4 methyl-5- [1- (4-fluorophenyl) -cyclopropyl] -4H- [1, 2, 4] triazol-3-yl} benzamide, 4- [4-isopropyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] -triazol-3-yl] benzamide, 4-. { 5- [1- (4-fluorophenyl) -cyclopropyl] -4-isopropyl-4H- [1,2, 4] triazol-3-yl} benzamide, 4-chloro-3-. { 5- [1- (4-fluorophenyl) -cyclopropyl] -4-methyl-4H- [1,2, 4] triazol-3-yl} benzamide, 4-chloro-3-. { 5- [1-phenylcyclopropyl] -4-methyl-4H- [1, 2,4] triazol-3-yl} benzamide, 3-chloro-4- [4-ethyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] benzamide, 3-chloro-4-. { 4-ethyl-5- [1- (4-fluorophenyl) cyclopropyl] -4H- [1,2, 4] triazol-3-yl} benzamide, 3- [4-isopropyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] -triazol-3-yl] benzamide, 3-. { 5- [1- (4-fluorophenyl) -cyclopropyl] -4-isopropyl-4H- [1,2, 4] triazol-3-yl} benzamide, a prodrug thereof or a pharmaceutically acceptable salt thereof. (16) The triazole compound of (1) above, which is N-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] phenyl} -l-morpholinecarboxamide, 3-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -phenyl} -l, 1-dimethylurea,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] -phenyl} urea, N-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,] triazol-3-yl] phenyl} -l- (4-methoxypiperidine) -carboxamide, N-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1, 2,4] triazol-3-yl] -phenyl} -! - (3-hydroxypiperidine) -carboxamide, N-. { 3-Chloro-4- [4-methyl-5- (l-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -phenyl} -l- (4-hydroxypiperidine) -carboxamide, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] -phenyl} -3-methoxyurea, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} -3-hydroxy-3-methylurea, 1- (3-chloro-4-. {5- [1- (4-fluorophenyl) -cyclopropyl] -4-methyl-4H- [1,2,4] triazole- 3-yl.}.-Phenyl) -3-methoxyurea, 1- (4-. {5- [1- (-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1, 2,] triazole-3- il.}. -phenyl) -3-methoxyurea, 1- (3. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,4,4] triazole-3-. il.}. phenyl) -3-methoxyurea, a prodrug thereof or a pharmaceutically acceptable salt thereof. (17) The triazole compound of (1) above, which is 3-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] -phenyl} oxazolidin-2-one, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] phenyl} imidazolidin-2-one, 3- (3-chloro-4-. {5- [1- (4-fluoro-phenyl) -cyclopropyl] -4-methyl-4H- [1, 2, 4] triazole-3- il.} phenyl) oxazolidin-2-one, 3- (4-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,2,4] triazole-3- il.} phenyl) oxazolidin-2-one, 3- (4-chloro-3-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-methyl-4H- [1,2,4] triazol-3-yl.} phenyl) oxazolidin-2-one, 3- (3. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,2,4] triazol-3-yl.} phenyl) oxazolidin-2-one, a prodrug thereof or a pharmaceutically acceptable salt thereof. (18) A pharmaceutical composition comprising the triazole compound of any of (1) to (17) above, a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. (19) An inhibitor of HSD1 (11-beta-hydroxysteroid dehydrogenase 1) comprising the triazole compound of any of (1) to (17) above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component. (20) A therapeutic or prophylactic drug for diabetes, which comprises the triazole compound of any of (1) to (17) above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component. (21) A therapeutic or prophylactic drug for obesity, which comprises the triazole compound of any of (1) to (17) above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component. (22) A therapeutic or prophylactic drug for metabolic syndrome, which comprises the triazole compound of any of (1) to (17) above, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component. (23) A method for the treatment or prophylaxis of diabetes, which comprises administering an effective amount of the triazole compound of any of (1) to (17) above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal . (24) A method for the treatment or prophylaxis of obesity, which comprises administering an effective amount of the triazole compound of any of (1) to (17) above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal . (25) A method for the treatment or prophylaxis of metabolic syndrome, which comprises administering an effective amount of the triazole compound of any of (1) to (17) above, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal. (26) The method of (23) above, in which a different therapeutic drug for diabetes is used in combination. (27) The method of (26) above, in which the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an a-glucosidase inhibitor and an insulin sensitizer. (28) The method of (27) above, wherein the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of insulin, glibenclamide, tolbutamide, glycpypyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glibuzol, metformin hydrochloride, buformin hydrochloride, voglibose, acarbose and pioglitazone hydrochloride. (29) The method of (24) above, in which a different therapeutic drug for diabetes is used in combination. (30) The method of (29) above, wherein the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an a-glucosidase inhibitor and an insulin sensitizer. (31) The method of (30) above, wherein the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glibuzol, metformin hydrochloride, buformin hydrochloride, voglibose, acarbose and pioglitazone hydrochloride. (32) The method of (25) above, in which a different therapeutic drug for diabetes is used in combination. (33) The method of (32) above, wherein the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of an insulin preparation, a sulfonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an alpha-glucosidase inhibitor and an insulin sensitizer. (34) The method of (33) above, wherein the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of insulin, glibenclamide, tolbutamide, glycpypyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glibuzol, metformin hydrochloride, buformin hydrochloride, voglibose, acarbose and pioglitazone hydrochloride. (35) The method of (23) above, in which a different therapeutic drug for obesity is used in combination. (36) The method of (35) above, in which the different therapeutic drug for obesity is Mazindol. (37) The method of (24) above, in which a different therapeutic drug for obesity is used in combination. (38) The method of (37) above, in which the different therapeutic drug for obesity is Mazindol. (39) The method of (25) above, in which a different therapeutic drug for obesity is used in combination. (40) The method of (39) above, in which the different therapeutic drug for obesity is Mazindol. The triazole compound of the present invention shows markedly increased HSD1 inhibitory activity in vivo, which results in improved metabolic resistance.

DETAILED DESCRIPTION OF THE INVENTION The substituents and respective portions used in the present description are defined as follows. The "alkyl group" means a straight chain or branched chain alkyl group. Examples thereof include methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, neopentyl group, ter-pentyl group, group 1 ethylpropyl, hexyl group and the like. This is preferably a straight chain or branched chain alkyl group having from 1 to 6, more preferred from 1 to 4, carbon atoms. For R1, methyl, ethyl, propyl, isopropyl, butyl and isobutyl are preferred, and methyl and isopropyl are particularly preferred. The "cycloalkyl group" means a saturated cyclic alkyl group. Examples thereof include cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, cycloheptyl group, cyclo-octyl group and the like. This is preferably a cycloalkyl group having from 3 to 8, more preferred from 3 to 6, carbon atoms. For R1, cyclopropyl is preferred. When R1 is alkyl, the cycloalkyl group as a substituent on alkyl is preferably cyclopropyl. For Y, cyclopropyl, cyclobutyl and cyclopentyl are preferred, and cyclopropyl is particularly preferred. For, cyclopropyl, cyclobutyl and cyclopentyl are preferred, and cyclopropyl is particularly preferred. The "heterocycloalkyl group" means a saturated 5- to 7-membered heterocyclic group containing from 1 to 3 heteroatoms which are selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom. Examples thereof include tetrahydrofuryl group, tetrahydrothienyl group, pyrrolidinyl group, pyrazolidinyl group, imidazolidinyl group, oxazolidinyl group, thiazolidinyl group, tetrahydropyranyl group, dioxolanyl group, dioxanyl group, piperidinyl group, piperazinyl group, morpholinyl group and the like. For Y, piperidinyl is preferred. For Y2, dioxolanyl is preferred. The "alkenyl group" means a straight chain or branched chain alkenyl group. Examples thereof include vinyl group, 1-propenyl group, allyl group, 1-methyl-2-propenyl group, 1-butenyl group, 2-butenyl group, 3-butenyl group, 1-pentenyl group, 2-pentenyl group, 1-hexenyl group, 2-hexenyl group and the like. This is preferably a straight chain or branched chain alkenyl group having from 2 to 6, more preferred from 2 to 4, carbon atoms. When R1 is alkyl, the alkenyl group as an alkyl substituent is preferably vinyl. The "aryl group" means an aromatic hydrocarbon group. Examples thereof include phenyl group, naphthyl group, anthryl group and the like. This is preferably a phenyl or naphthyl group. For Ar1, Ar2, Ar3 and Ar4, phenyl and naphthyl are preferred, and phenyl is particularly preferred.

The "heteroaryl group" means a fused monocyclic 5- to 14-membered aromatic heterocyclic group containing from 1 to 3 heteroatoms which are selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom. Examples thereof include furyl group, thienyl group, pyrrolyl group, oxazolyl group, iso-oxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, indolyl group, isoindolyl group, benzofuranyl group, benzothienyl group, benzoimidazolyl group, benzothiazolyl group, benzoxazolyl group, indolizinyl group, quinolyl group, group isoquinolyl, quinazolinyl group, cinolinyl group, quinoxalinyl group, phthalazinyl group, acridinyl group, phenazinyl group, naphthyridinyl group and the like. Preferably this is a monocyclic or fused 5 to 10 membered aromatic heterocyclic group containing from 1 to 3 heteroatoms which are selected from the group consisting of nitrogen atom, oxygen atom and sulfur atom, which includes furyl group , thienyl group, pyrrolyl group, oxazolyl group, iso-oxazolyl group, thiazolyl group, isothiazolyl group, imidazolyl group, pyrazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, indolyl group, isoindolyl group, benzofuranyl group, benzothienyl group , benzoimidazolyl group, benzothiazolyl group, benzooxazolyl group and the like. For Ar1, thienyl, pyrrolyl and pyridyl are preferred. For Ar 2, thienyl, pyrrolyl, oxazolyl, isooxazolyl, thiazolyl, imidazolyl, pyrazolyl and pyridyl are preferred, and thienyl and pyridyl are particularly preferred. For Ar3 and Ar4, pyridyl is preferred. The "halogen atom" means fluorine atom, chlorine atom, bromine atom or iodine atom. Preferably, it is a fluorine atom or a chlorine atom. For R2 and R3, fluorine atom is preferred. In this case, Ar1 is particularly preferably phenyl, in which only the 4-position of the phenyl is substituted with fluorine atom. For R4 and R5, chlorine atom is preferred. In this case, Ar2 is particularly preferably phenyl, in which at least the 2-position of the phenyl is substituted with a chlorine atom. The "halogenoalkyl group" means a halogenoalkyl group in which the alkyl group "defined above is substituted with the" halogen atom "defined above Examples thereof include fluoromethyl group, difluoromethyl group, trifluoromethyl group, bromomethyl group, chloromethyl group, 1,2-dichloroethyl group, 2-dichloroethyl group, 2,2,2-trifluoroethyl group and the like This is preferably a straight-chain or branched-chain halogenoalkyl group having 1 to 6, more preferred 1 to 4, carbon atoms, particularly preferably a trifluoromethyl group The "alkoxy group" means a straight-chain or branched-chain alkoxy group Examples thereof include methoxy group, ethoxy group, propoxy group, isopropoxy group, butoxy group , isobutoxy group, tert-butoxy group, pentyloxy group, hexyloxy group and the like, this is preferably a straight-chain or branched-chain alkoxy group having from 1 to 6, more preferred 1 to 4, atom carbon. For R2 and R3, methoxy is preferred. For R 4 and R 5, methoxy, ethoxy and isopropoxy are preferred. The group "halogenoalkoxy" means a halogenoalkoxy group in which the "alkoxy group" defined above is substituted with the "halogen atom" defined above. Examples thereof include fluoromethoxy group, difluoromethoxy group, trifluoromethoxy group, bromomethoxy group, chloromethoxy group, 1,2-dichloroethoxy group, 2,2-dichloroethoxy group, 2, 2,2-trifluoroethoxy group and the like. This is preferably a straight chain or branched chain halogenoalkoxy group having from 1 to 6, more preferred 1 to 4, carbon atoms. The group "alkoxyalkyl" means an alkoxyalkyl group in which the "alkyl group" defined above is substituted with the "alkoxy group" defined above. Examples thereof include methoxymethyl group, ethoxymethyl group, propoxymethyl group, isopropoxymethyl group, butoxymethyl group, isobutoxymethyl group, tert-butoxymethyl group, 2-methoxyethyl group, pentyloxymethyl group, hexyloxymethyl group and the like. This is preferably an alkoxyalkyl group in which the alkyl group is a straight-chain or branched-chain alkyl group having from 1 to 6., more preferred 1 to 4, carbon atoms and the alkoxy group is a straight-chain or branched-chain alkoxy group having from 1 to 6, more preferred from 1 to 4, carbon atoms. For R23, R24 and R41, methoxymethyl and 2-methoxyethyl are preferred. The group "-CO-alkyl" means an alkylcarbonyl group having the "alkyl group" defined above as the alkyl portion. Examples thereof include acetyl group, propionyl group, butyryl group, isobutyryl group, valeryl group, isovaleryl group, pivaloyl group, pentanoyl group, hexanoyl group and the like. This is preferably an alkylcarbonyl group in which the alkyl portion is a straight chain or branched chain alkyl group having from 1 to 6, more preferred 1 to 4, carbon atoms. For R9, R10, R21, R22, R33, R34, R38, R39, R48 and R49, acetyl, propionyl, butyryl and isobutyryl are particularly preferred. The group "-CO-0-alkyl" means an alkyloxycarbonyl group having the "alkyl group" defined above as the alkyl moiety. Examples thereof include methyloxycarbonyl group, ethyloxycarbonyl group, propyloxycarbonyl group, isopropyloxycarbonyl group, butyloxycarbonyl group, isobutyloxycarbonyl group, sec-butyloxycarbonyl, tert-butyloxycarbonyl group, pentyloxycarbonyl group, isopentyloxycarbonyl group, neopentyloxycarbonyl group, tert-pentyloxycarbonyl group, 1- ethylpropyloxycarbonyl, hexyloxycarbonyl group and the like. This is preferably an alkyloxycarbonyl group in which the "alkyl portion" is a straight chain or branched chain alkyl group having from 1 to 6, more preferred from 1 to 4, carbon atoms. For R21, R22, R38, R39, R48 and R49, methyloxycarbonyl, ethyloxycarbonyl, propyloxycarbonyl, isopropyloxycarbonyl and tert-butyloxycarbonyl are particularly preferred. The group "-NH-alkyl" means an alkylamino group having the "alkyl group" defined above as the alkyl portion. Examples thereof include methylamino group, ethylamino group, propylamino group, isopropylamino group, butylamino group, isobutylamino group, sec-butylamino, tert-butylamino group, pentylamino group, isopentylamino group, tert-pentylamino group, hexylamino group and the like. This is preferably an alkylamino group in which the alkyl portion is a straight chain or branched chain alkyl group having from 1 to 6, more preferred from 1 to 4, carbon atoms. For R26, R27, R32 and R52, methylamino, ethylamino, propylamino and isopropylamino are particularly preferred. The group "-N (-alkyl) 2" means a dialkylamino group having the "alkyl group" defined above as the alkyl portion. Examples thereof include dimethylamino group, diethylamino group, dipropylamino group, di-isopropila ino, dibutylamino group, di-isobutylamino, amino group di (sec-butyl), di (tert-butyl) amino, dipentylamino group, di-isopentylamino, di (ter-pentyl) amino group, dihexylamino group, N-ethyl-N-methylamino group, N-methyl-N-propylamino group, N-ethyl-N-propylamino group and the like. This is preferably a dialkylamino group in which the alkyl portion is a straight chain or branched chain alkyl group having from 1 to 6, more preferred from 1 to 4, carbon atoms. For R 26, R 27, R 32 and R 52, dimethylamino, diethylamino and N-ethyl-N-methylamino are particularly preferred. The "alkyl" portions of "alkylamino" and "dialkylamino group" are optionally substituted with 1 to 5 substituents each independently selected from halogen, -CF3, -OH, alkoxy group, haloalkoxy group , -N (R9) (R10) (R9 and R10 are each independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -N02, cycloalkyl group, alkenyl group, -CO-R11 (R11 is -OH, alkoxy group, alkyl group or -N (R12) (R13) in which R12 and R13 are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group. In this case, the substituent "aryl group" and "heteroaryl group" are optionally substituted with 1 to 3 substituents each independently selected from halogen atom, halogenoalkyl group, alkyl group, - (CH2) n -OH (n = 0-3), ~ N (R9) (R10) (R9 and R10 are independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -N02, alkoxy group, cycloalkyl group, alkenyl group, -CO-R11 (R11 is -OH, alkoxy group, alkyl group or -N (R12) (R13) in which R12 and R13 are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group. The "aryl group" and the "heteroaryl group" for R2, R3, R6, R14, R15, R16, Ar3 and Ar4 are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom, halogenoalkyl group, alkyl group, group - (CH2) n-OH (n = 0-3), -N (R9) (R10) (R9 and R10 are each independently hydrogen atom, alkyl group or -CO- alkyl), -CN, -N02, alkoxy group, cycloalkyl group, alkenyl group, -CO-R11 group (R11 is -OH, alkoxy group, alkyl group or -N (R12) (R13) in which R12 and R13 are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group. The "cycloalkyl group" and the "heterocycloalkyl group" for Y and Yi are optionally substituted with 1 to 3 substituents each independently selected from halogen atom, halogenoalkyl group, alkyl group, group - (CH2) n -OH (n = 0-3), -N (R9) (R10) (R9 and R10 are each independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -N02, alkoxy group, cycloalkyl group, alkenyl group, -CO-R11 group (R11 is -OH, alkoxy group, alkyl group or -N (R12) (R13) in which R12 and R13 are each independently hydrogen atom or alkyl group) , aryl group and heteroaryl group.

The "alkyl group" and the "alkoxy group" for R4 and R5, and the "alkoxy group" for R37 are optionally substituted with 1 to 5 substituents each independently selected from a halogen atom, -CF3, -OH, alkoxy group, halogenoalkoxy group, group -N (R9) (R10) (R9 and R10 are each independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -N02, cycloalkyl group, alkenyl group, -CO-R11 (R11 is -OH, alkoxy group, alkyl group or -N (R12) (R13) in which R12 and R13 are each independently hydrogen atom or alkyl group), aryl group and heteroaryl group. In this case, the substituent "aryl group" and "heteroaryl group" are optionally substituted with 1 to 3 substituents each independently selected from halogen atom, halogenoalkyl group, alkyl group, group - (CH2) n -OH (n = 0-3), -N (R9) (R10) (R9 and R10 are independently hydrogen atom, alkyl group or -CO-alkyl), -CN, -N02, alkoxy group, cycloalkyl group , alkenyl group, -CO-R11 group (R11 is -OH, alkoxy group, alkyl group or -N (R12) (R13) in which R12 and R13 are each independently hydrogen atom or alkyl group), group aryl and heteroaryl group. The substituents "halogen atom", "halogenoalkyl group", "alkyl group", "alkoxy group", "halogenoalkoxy group", "cycloalkyl group", "alkenyl group", "aryl group" and "heteroaryl group" mentioned above are as defined above. R4 and R5 in combination can form -O-alkylene-0-. In this case, "alkylene" means a divalent hydrocarbon. Examples thereof include methylene, ethylene, propylene, butylene, pentylene, hexylene, and the like. This is preferably an alkylene having from 1 to 6, more preferred from 1 to 4, carbon atoms, particularly preferably methylene. In the aforementioned formulas, Z is preferably - (CH (R1)) P- and p is 0; And preferably it is a cycloalkyl group of C3_s; Ar1 is preferably a phenyl group; Ar2 is preferably a phenyl group; R1 is preferably an alkyl group; R2 is preferably a hydrogen atom; R3 is preferably a halogen atom; R4 is preferably a hydrogen atom, a halogen atom or an alkoxy group; R5 is preferably -CO-N (R28) (R29) (in which R28 and R29 are preferably each independently a hydrogen atom or an alkyl group) or -N (R30) (R31) (in which which R30 is preferably a hydrogen atom and R31 is preferably _ (CH2) x-CO-R41 in which X is preferably 0 and R41 is preferably an alkoxy group, or X is preferably 0 and R41 is preference - (CH2) SN (R42) (R43) in which "s" is preferably O, R42 is preferably a hydrogen atom and R43 is preferably an alkoxy group, or R30 and R31 preferably are joined to form wherein X3 is preferably -CO- and X preferably is -0-). The "pharmaceutically acceptable salt" can be any salt as long as it forms a non-toxic salt with a triazole compound represented by the aforementioned formula. For example, this can be obtained by reaction with inorganic acids such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid and the like; organic acids such as oxalic acid, malonic acid, citric acid, fumaric acid, lactic acid, malic acid, succinic acid, tartaric acid, acetic acid, trifluoroacetic acid, gluconic acid, ascorbic acid, methylsulfonic acid, benzylsulfonic acid and the like; inorganic bases such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, ammonium hydroxide and the like; organic bases such as methylamine, diethylamine, triethylamine, triethanolamine, ethylenediamine, tris (hydroxymethyl) ethylamine, guanidine, choline, cinchonin, N-methyl-D-glucamine and the like; or amino acids such as lysine, histidine, arginine, alanine and the like. In the present invention, a form containing water, a hydrate and a solvate of each compound are also included therein. In addition, the triazole compound represented by the aforementioned formula includes several isomers. For example, the E form and the Z form are present as geometric isomers, and when an asymmetric carbon atom is present, enantiomers and diastereomers are present as stereoisomers based thereon. In some cases, a tautomer may be present. Accordingly, the present invention encompasses all of these isomers and mixtures thereof. The present invention also encompasses prodrugs and metabolites of the triazole compound represented by the formula. A "prodrug" is a derivative of the compound of the present invention, which has a chemically or metabolically decomposable group which, after being administered to a living organism, is restored to its original compound form and exhibits its efficacy intrinsic, and which includes complexes and salts free of a covalent bond. For example, ester-type derivatives known as prodrugs in the field of pharmaceutical agents can be used.

When the compound of the present invention is used as a pharmaceutical preparation, it is usually mixed with a carrier, excipient, diluent, extender, disintegrant, stabilizer, preservative, pH regulator, emulsifier, fragrance, coloring agent, sweetening agent, thickener, modifier (corrigent), dissolving aids and other pharmaceutically acceptable additives known per se, such as water, vegetable oil, alcohols such as ethanol, benzyl alcohol and the like, polyethylene glycol, glycerol triacetate, gelatin, lactose, carbohydrates such as starch and the like, magnesium stearate, talc, lanolin, petrolatum and the like, and are produced in the form of a tablet, pill, powder, granule, suppository, injection, eye drops, liquid, capsule, troches, aerosol, elixir, suspension, emulsion , syrup and the like using a conventional method for administration by systemic or local, oral or parenteral route. Although the dose of the compound of the present invention varies according to age, body weight, symptom, disease to be treated, method of administration and the like, it is generally 50 mg to 800 mg for an adult per administration, the which is supplied one to several times per day. The compound of the present invention can be administered to a mammal (human, mouse, rat, rabbit, dog, cat, bovine, pig, monkey, etc.) as an inhibitor of HSD1, a prophylactic or therapeutic drug for diabetes, a drug prophylactic or therapeutic for diabetic complication (retinopathy, nephropathy, neuropathy, cardiac infarction and cerebral infarction based on arteriosclerosis, etc.), a prophylactic or therapeutic drug for hyperlipidemia, a prophylactic or therapeutic drug for obesity, neurodegenerative disease and the like, or a drug prophylactic or therapeutic for diseases mediated by HSD1. The compound of the present invention can be administered to a mammal concurrently with another therapeutic drug for diabetes or obesity for the purpose of prophylaxis or treatment for diabetes. In the present invention, the "therapeutic drug for diabetes" encompasses therapeutic drugs for diabetic complications. Also, the compound of the present invention can be administered in combination with other therapeutic drugs for diabetes or obesity to a mammal for the prophylaxis or treatment of obesity. In the case of a combined administration, the compound of the present invention can be administered simultaneously with other therapeutic drugs for diabetes or other therapeutic drugs for obesity (hereafter referred to as a combined pharmaceutical agent) or it can be administered at intervals of time. In the case of a combined administration, a pharmaceutical composition containing the compound of the present invention and a combined pharmaceutical agent can be administered. Alternatively, a pharmaceutical composition containing the compound of the present invention and a pharmaceutical composition containing a combined pharmaceutical agent can be administered separately. The routes of administration of the respective pharmaceutical compositions may be the same or different. In the case of a combined administration, the compound of the present invention can be administered at a dose of 50 mg to 800 mg per administration, which is administered one to several times per day. In addition, the compound can be administered at a smaller dose. The combined pharmaceutical agent can be administered at a dose generally used for the prophylaxis or treatment of diabetes or obesity or at a dose smaller than that. As another therapeutic drug for diabetes which will be used for the combined administration, insulin preparation, sulphonylurea, insulin secretagogue, sulfonamide, biguanide, α-glucosidase inhibitor, insulin sensitizer and the like can be mentioned. For example, insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glybuzole, metformin hydrochloride, buformin hydrochloride, voglibose, acarbose, pioglitazone hydrochloride and the like can be used for combined administration with the compound of the present invention. As another therapeutic drug for obesity that will be used for the combined administration, there may be mentioned, for example, mazindol. An example of the production method of the triazole compound of the present invention is described below in the following section, which does not limit the production method of the compound of the present invention. Even in the absence of description in the production method, efficient production can be obtained by introducing, when necessary, a protective group into a functional group followed by deprotection in a subsequent step, exchanging the order of the respective methods and production steps, and similar. The post-reaction treatment can be applied by a typical method by selecting or combining conventional methods as necessary, such as isolation and purification, crystallization, recrystallization, silica gel chromatography, preparative HPLC and the like.

Production method 1 In this production method, a triazole compound is produced, in which the atom linked to the 2- or 5- position (in which the substituent Z is attached) of the triazole ring is carbon, and the method includes any of the following steps. wherein each symbol is as defined above, with the proviso that the atom linked to the 2- or 5- position (in which the Z substituent is attached) of the triazole ring of the triazole compound to be formed is carbon . Synthesized acyl hydrazide (1) is reacted by a known method and thioimidate (2) synthesized by a known method in a solvent to produce the triazole (3). As the solvent, there may be mentioned methanol, ethanol, n-propanol, n-butanol, isopropanol, acetonitrile, diethyl ether, tetrahydrofuran (THF), 1,4-dioxane, N, N-dimethylformamide, dimethyl sulfoxide, dichloromethane, , 2-dichloroethane, chloroform, benzene, chlorobenzene, o-dichlorobenzene, toluene, xylene, pyridine, 2,6-lutidine, 2, 4, 6-collidine, acetic acid, water, or a mixed solvent thereof. The reaction temperature is preferably 20 ° C-250 ° C. When acylhydrazide (1) or thioimidate (2) is a salt, the reaction is carried out in the presence of a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, bicarbonate of potassium, sodium acetate, potassium acetate, sodium hydride, potassium hydride, triethylamine, N, N-di-isopropylethylamine, pyridine and the like.

Alternatively, triazole (3) can be obtained according to a similar method from thioimidate (4) synthesized by a known method and acyl hydrazide (5) synthesized by a known method.

Production method 2 In this production method, a triazole compound is produced, in which the atom linked to the 2- or 5- position (in which the Z substituent is attached) of the triazole ring is nitrogen, and the method includes the following steps. wherein each symbol is as defined above, with the proviso that the atom linked to the 2- or 5- position (in which the Z substituent is attached) of the triazole ring of the triazole compound to be formed is nitrogen .

The triazole (7) can be obtained by reacting isothiourea (6) synthesized by a known method with acyl hydrazide (5) synthesized by a known method in a solvent. As the solvent, there may be mentioned methanol, ethanol, n-propanol, n-butanol, isopropanol, acetonitrile, diethyl ether, tetrahydrofuran (THF), 1,4-dioxane, N, N-dimethylformamide, dimethyl sulfoxide, dichloromethane, , 2-dichloroethane, chloroform, benzene, chlorobenzene, o-dichlorobenzene, toluene, xylene, pyridine, 2,6-lutidine, 2, 4, 6-collidine, acetic acid, water, or a mixed solvent thereof. The reaction temperature is preferably 20 ° C-250 ° C. When the isothiourea (6) or acyl hydrazide (5) is a salt, the reaction is carried out in the presence of a base such as sodium hydroxide, potassium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, sodium acetate, potassium acetate, sodium hydride, potassium hydride, triethylamine, N, N-di-isopropylethylamine, pyridine and the like. The production methods described in this description are examples of the production methods of the compounds of the present invention, and the compounds in addition to the compounds explained above can be produced by combining conventional methods known in the field of organic synthesis chemistry, EXAMPLES The triazole compound represented by the formula of the present invention and the production method thereof are explained in greater detail in the following section with reference to the examples, which should not be considered as limiting.

EXAMPLE 1-1 Production of 3 ', 5'-dichloro-4- (5- (1- (4-chlorophenyl) cyclopropyl) -4-methyl-4H- [1,2,4] riazol-3-yl hydrochloride ) - 3,4,5,6-etrahydro-2H- [1,4 '] bipyridyl 3 ', 5'-Dichloro-N-methyl-3,4,5,6-tetrahydro-2H- [1,4'] bipyridinyl-4-imidathio-carboxylic acid methyl ester (452 mg) and 1- (4-chlorophenyl) -cyclopropan-carbohydrazide (178 mg) in 1,4-dioxane (1.8 ml) and water (0.4 ml), sodium acetate (83 mg) are added and the mixture is refluxed overnight. The reaction solution is concentrated and extracted with ethyl acetate.

The ethyl acetate layer is washed successively with saturated aqueous sodium bicarbonate solution, water and saturated brine, dried over anhydrous sodium sulfate and concentrated to dryness. The residue obtained is purified by chromatography with silica gel (chloroform-acetone = 1: 1). After this, 4N hydrogen chloride solution in ethyl acetate (0.16 ml) is added and the mixture is concentrated to dryness to obtain the title compound (203 mg). XH-NMR (400MHz, DMS0-d6) d 1.53-1.69 (4H, m), 1.91-2. 08 (4H, m), 3.34-3.62 (5H,), 3.62 (3H, s), 7.22 (2H, d, J = 6.0 Hz), 7.38-7.41 (2H, m), 8.47 (2H, s).

EXAMPLE 2-1 Production of 1- [4-ptethyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -4-phenylpiperidine Methyl N-methyl-4-phenylpiperidin-1-imidathiocarboxylate hydodide (452 mg) and 1-phenylcyclopropane-carbohydrazide (176 mg) in 1,4-dioxane (2 ml) are suspended and water (0.4 ml) is added, Sodium acetate (98 mg) and the mixture is heated to reflux overnight. The reaction solution is concentrated and extracted with ethyl acetate. The ethyl acetate layer is washed successively with saturated aqueous sodium bicarbonate solution, water and saturated brine, dried over anhydrous sodium sulfate and concentrated to dryness. The residue obtained is purified by chromatography with silica gel (chloroform: acetone = 1: 1). After this, 4N hydrogen chloride solution in ethyl acetate (0.25 ml) is added and the mixture is concentrated to dryness. Acetone is added and the insoluble solids are collected by filtration and dried to obtain the title compound (117 mg). 1 H-NMR (300MHz, DMS0-d 6) d 1.50-1.66 (4H,), 1.76-1.91 (4H, m), 2.70-2.80 (HH, m), 3.19-3.28 (2H, m), 3.43 (3H, s), 3.77 (2H, d, J = 12.8 Hz), 7.20-7.39 (10H, m).

EXAMPLES 1-2 to 1-161 In the same manner as in Example 1-1, and using other conventional methods as necessary, a triazole compound is produced. The structural formula and the property values of each example compound are shown in the following table.

EXAMPLES 2-2 to 2-99 In the same manner as in Example 2-1, and using other conventional methods as necessary, a triazole compound is produced. The structural formula and the property values of each example compound are shown in the following table.

EXPERIMENTAL EXAMPLE Inhibitory activity of HSD (hydroxysteroid dehydrogenase 1) activity in vivo The inhibitory activity of HSD1 is examined by quantitative determination using a SPA system (scintillation proximity test) of the suppressive action on the conversion of cortisone to cortisol using human HSD1 (hereinafter referred to as HSD1 recombinant) which is expressed using a baculovirus system as a source of the enzyme. For the reaction, a reagent is added to a 96-well plate (96-well Opti-plates ™ -96 (Packard)) until the next final concentration and a volume of 100 μl is reacted at room temperature for 90 minutes. The reaction solution used is 0.1 μg / ml of Recombinant HSD1, 500 μM of NADPH, 16 nM of 3 H-cortisone (Amersham Biosciences, 1.78 Tbq / mol) dissolved in PBS containing 0.1% BSA (Sigma) and the test drug are 2 μl of a solution of the compound (dissolved in DMSO). After 90 minutes, the reaction is stopped by adding PBS (40 μl, containing 0.1% BSA (Sigma)) containing 0.08 μg of anti-cortisol monoclonal antibody, from mouse, (East Coast Biologics), 365 μg of globules for binding of mouse SPA PVT antibody (Amersham Biosciences) and 175 μM of carbenoxolone (Sigma) to the reaction solution. After the reaction is complete, the plate is incubated overnight at room temperature and the radioactivity is measured using a Topcount apparatus (Packard). For control, the value (0% inhibition) of the cavity containing 2 μl of DMSO is used in place of the test drug, and for the positive control, the value (100% inhibition) of the cavity is used. contains carbenoxolone in place of the test drug at the final concentration of 50 μM. The inhibition (%) of the test drug is calculated by the equation ((value of the control - value of the test drug) / (value of the control - value of the positive control)) x 100 (%).

The IC50 value is analyzed using software for computer-based curve fitting. The results obtained are shown in the following table. 15 20 25 10 15 20 25 10 15 20 25 10 15 20 25 10 15 20 25 In the table above, "+" in the Cl50 column means lOnM < IC50 < 1,000 nM and "++" in the IC50 column means IC50 < 10 nM. In the same manner described in Example 1-1 or 2-1, and using other conventional methods as necessary, the triazole compounds shown in the following table can also be produced.

As mentioned above, the triazole compound of the present invention has superior HSD1 inhibitory activity and is useful as an inhibitor of HSD1, a therapeutic drug for diabetes or a therapeutic drug for obesity.

Claims

NOVELTY OF THE INVENTION Having described the present invention, it is considered as a novelty and therefore the content of the following is claimed as property: CLAIMS

1. - A triazole compound represented by the following formula: wherein R1 is an alkyl group or a cycloalkyl group in which the alkyl group and the cycloalkyl group are optionally substituted with 1 to 5 substituents each independently selected from a halogen atom, -CF3, - OH, -NH2, an alkoxy group, a cycloalkyl group, an alkenyl group, -COOH, -CO-O-alkyl, -CO-N (R7) (R8), -N (R7) -CO-R8, a group aryl and a heteroaryl group in which R7 and R8 are each independently a hydrogen atom or an alkyl group, and the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents which are each independently selected from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group , -CO-R11, an aryl group and a heteroaryl group in which n is 0-3, R9 and R10 are each independently a hydrogen atom, an alkyl or -CO-alkyl group, and R11 is -OH, an alkoxy group, an alkyl group or -N (R12) (R13) in which R12 and R13 are each independently a hydrogen atom or a group I rent; Y is a cycloalkyl group or a heterocycloalkyl group in which the cycloalkyl group and the heterocycloalkyl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom, a halogenoalkyl group, an alkyl group , - (CH) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group (n , R9, R10 and R11 are as defined above); Ar1 is an aryl group or a heteroaryl group; R2 and R3 are each independently a hydrogen atom, a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group or a heteroaryl group in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents each of which are independently selected from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group , -CO-R11, an aryl group and a heteroaryl group (n, R9, R10 and R11 are as defined above); Z is - (CH (R14)) P-, - (CH (R14)) p-N (R16) - (CH (R15)) q- or wherein Yi is a cycloalkyl group or a heterocycloalkyl group in which the cycloalkyl group and the heterocycloalkyl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-0H, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a group heteroaryl (n, R9, R10 and R11 are as defined above), ?? "p is 0-3, q is 0-3, R14 and R15 are each independently a hydrogen atom, a halogen atom, a halogenoalkyl group, an alkyl group, (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group or a heteroaryl group in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents which are each independently selected from starting from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-0H, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group (n, R9, R10 and R11 are as defined above), and R16 is a hydrogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, - (CH2) n_C0-R11, a cycloalkyl group, a alkenyl group, an aryl group or a heteroaryl group in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom, a halogenoalkyl group, a group alkyl, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group ( n, R9, R10 and R11 are as defined above); Ar2 is an aryl group, a heteroaryl group or in which Xi is - (CH2) t_ in which t is 0-2, Vi is = CH- or = N-, and i is -C (R17) (R18) -, -0-, -S-, - S02-, -SO-, -CO- or -N (R19) - in which R17 and R18 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a halogenoalkyl group, - (CH2) r-0H, -CO-R20, -N (R21) (R22) or -Li-Ar3 in which r is 0-3, R20 is -OH, an alkoxy group, an alkoxyalkyl group or -N (R23) ( R24) in which R23 and R24 are each independently a hydrogen atom, an alkyl group, - (CH2) s-0H, an alkoxyalkyl group, or in combination form / \ -N X, \ / " where s is 0-3, X2 is -0-, - (CH2) t ~ o -N (R25) - in which t is as defined above and R25 is a hydrogen atom, -CO-R26, -S02-R26 or - (CH2) U-Ar4 in which R26 is an alkyl group, alkoxy group, -NH-alkyl or -N (-alkyl) 2, "u" is 0-3, and Ar4 is an aryl group or a heteroaryl group in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, a alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group (n, R9, R10 and R11 are as defined above), Li is - (CH2) V-, -O- or -C0- wherein v is 0-3, and Ar3 is an aryl group or a heteroaryl group in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents which are each independently selected from from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, a group aryl and a heteroaryl group (n, R9, R10 and R11 are as defined above), and R21 and R22 are each independently a hydrogen atom, an alkyl group, -CO-alkyl, -CO-0-alkyl or -Li-Ar3 (Li and Ar3 are as defined above), and R19 is a hydrogen atom, -CO-R26, -S02-R26 or - (CH2) U-Ar4 (R26, "u" and Ar4 are as defined above); and R4 and R5 are each independently a hydrogen atom, a halogen atom, -OH, -N02, -CN, an alkyl group, an alkoxy group, -CO-R27, -S02-R27, -C0- N (R28) (R29) or -N (R30) (R31) in which the alkyl group and the alkoxy group are optionally substituted with 1 to 5 substituents each independently selected from a halogen atom, -CF3, -OH, an alkoxy group, a halogenoalkoxy group, -N (R9) (R10), -CN, -N02, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group ( R9, R10 and R11 are as defined above), in which the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom, a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a group heteroaril or (n, R9, R10 and R11 are as defined above) R27 is -OH, an alkoxy group, an alkyl group, -NH2, -NH-alkyl or - (-alkyl) 2, R28 and R29 are each independently a hydrogen atom, an alkyl group or - (CH2) W-R32, in which is 0-3 and R32 is -OH, -CF3, an alkoxy group, -CONH2 or -N (R33) (R34) wherein R33 and R34 are each independently a hydrogen atom, an alkyl group, -CO-alkyl, or in combination form (X2 is as defined above) or R28 and R29 in combination form X3 R36 wherein X3 is -CO-, -CH2- or -CH2-CH2-, X4 is -O-, - (CH2) t-, -N (R25) - or wherein Y2 is cycloalkyl or heterocycloalkyl and "t" and R25 are as defined above, and R35 and R36 are each independently a hydrogen atom, a halogen atom, an alkyl group optionally substituted with -OH, - OH, -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R37, -N (R38) (R39) in which R37 is -OH, an alkoxy group, -NH2, -NHalkyl , -N (-alkyl) 2 or / \ i X2 \ / (X2 is as defined above) in which the alkyl group in -NH-alkyl and -N (-alkyl) 2 and the alkoxy group are optionally substituted with 1 to 5 substituents which are each independently selected from a halogen atom, -CF3, -OH, an alkoxy group, a halogenoalkoxy group, -N (R9) (R10), -CN, -N02, a cycloalkyl group, an alkenyl group, -CO-R11, an aryl group and a heteroaryl group (R9, R10 and R11 are as defined above), wherein the aryl group and the heteroaryl group are optionally substituted with 1 to 3 substituents each independently selected from a halogen atom , a halogenoalkyl group, an alkyl group, - (CH2) n-OH, -N (R9) (R10), -CN, -N02, an alkoxy group, a cycloalkyl group, an alkenyl group, -CO-R11, a aryl group and a heteroaryl group (n, R9, R10 and R11 are as defined above), and R38 and R39 are each independently a hydrogen atom geno, an alkyl group, -CO-alkyl or -C0-0-alkyl, and R30 and R31 are each independently a hydrogen atom, an alkyl group optionally substituted with -OH, -S02-R40, - (CH2 ) x-CO-R41 or / \ - v2 w2 \ / wherein x is 0-3, R40 is an alkyl group or -NH2, R41 is a hydrogen atom, an alkyl group optionally substituted with -OH, -OH, an alkoxy group, an alkoxyalkyl group or - (CH2) SN (R42) (R43) wherein "s" is as defined above and R42 and R43 are each independently a hydrogen atom, an alkyl group, -OH, an alkoxy group, or in combination form (X3, X4, R35 and R36 are as defined above), V2 is = CH- or = N- and W2 is -C (R44) (R45) -, -0- or -N (R46) - in which R44 and R45 are each independently a hydrogen atom, an alkyl group, an alkoxy group, a halogenoalkyl group, - (CH2) r-OH, -CO-R47 or -N (R48) (R49) in which r is as defined above, R47 is -OH, an alkoxy group, an alkoxyalkyl group, N (R50) (R51) in which R50 and R51 are each independently a hydrogen atom, an alkyl group, - ( CH2) s-OH ("s" is as defined above) or an alkoxyalkyl group, and R48 and R49 are each independently a hydrogen atom, an alkyl group, -CO-alkyl or -CO-O-alkyl , and R46 is a hydrogen atom, -CO-R52 or -S02-R52 in which R52 is an alkyl group, an alkoxy group, -NH-alkyl or -N (-alkyl) 2 or R30 and R31 in combination form (X3, X4, R35 and R36 are as defined above), or R4 and R5 in combination can form -O-alkylene-O-, a prodrug thereof or a pharmaceutically acceptable salt thereof.

2. The triazole compound according to claim 1, characterized in that Z is - (CH (R14)) p- and p is 0, a prodrug thereof or a pharmaceutically acceptable salt thereof.

3. The triazole compound according to claim 2, characterized in that Y is a C3-8 cycloalkyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof.

4. The triazole compound according to claim 3, characterized in that Ar1 is a phenyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof.

5. The triazole compound according to claim 4 > characterized in that R2 and R3 are each independently a halogen atom or a hydrogen atom, a prodrug thereof or a pharmaceutically acceptable salt thereof.

6. The triazole compound according to any of claims 1 to 5, characterized in that Ar2 is a phenyl group, R4 is a hydrogen atom, a halogen atom or an alkoxy group and R5 is -C0-N (R28 ) (R29), a prodrug thereof or a pharmaceutically acceptable salt thereof.

7. - The triazole compound according to claim 6, characterized in that R28 and R29 are each independently a hydrogen atom or an alkyl group, a prodrug thereof or a pharmaceutically acceptable salt thereof.

8. The triazole compound according to any of claims 1 to 5, characterized in that Ar2 is a phenyl group, R4 is a hydrogen atom or a halogen atom and R5 is -N (R30) (R31) in the which R30 is a hydrogen atom and R31 is - (CH2) X-C0-R41, a prodrug thereof or a pharmaceutically acceptable salt thereof.

9. The triazole compound according to claim 8, characterized in that X is 0 and R41 is an alkoxy group, a prodrug thereof or a pharmaceutically acceptable salt thereof.

10. The triazole compound according to claim 8, characterized in that X is 0 and R41 is - (CH2) S-N (R42) (R43), a prodrug thereof or a pharmaceutically acceptable salt thereof.

11. The triazole compound according to claim 10, characterized in that "s" is 0, R42 is a hydrogen atom and R43 is an alkoxy group, a prodrug thereof or a pharmaceutically acceptable salt thereof.

12. - The triazole compound according to any of claims 1 to 5, characterized in that Ar2 is a phenyl group, R4 is a hydrogen atom and R5 is -N (R30) (R31) in which R30 and R31 are bound to to form and X3 is -CO-, a prodrug thereof or a pharmaceutically acceptable salt thereof.

13. The triazole compound according to claim 12, characterized in that X4 is -0-, a prodrug thereof or a pharmaceutically acceptable salt thereof.

14. The triazole compound according to claim 1, which is: 3-chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4H- [1,2,4] triazole- 3-yl] -benzamide,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] benzoyl} morpholine, 3-chloro-N-methyl-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1, 2, 4] triazol-3-yl] benzamide, 3-chloro-N, N- dimethyl-4- [4-methyl-5- (1-phenyl-cyclo-propyl) -4H- [1, 2,] triazol-3-yl] -benzamide, 3-chloro-N- (2-hydroxy-ethyl) -4 - [4-methyl-5- (1-phenyl-cyclopropyl) -4H- [1,2, 4] triazol-3-yl] benzamide, 3-chloro-N-isopropyl-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1, 2, 4] triazol-3-yl] benzamide,. { 3-Chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4H [1,2, 4] triazol-3-yl] benzoyl} piperidine,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H [1,2, 4] triazol-3-yl] benzoyl} - (4-hydroxy) piperidine, N-carbamoylmethyl-3-chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4H- [1,2,4] triazol-3-yl] benzamide, 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] -N- (2,2,2-trifluoro-ethyl) -benzamide , N- (2-acetylamino) ethyl-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2, 4] triazol-3-yl] benzamide, 3-chloro- N- (2-methoxy) -ethyl-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzamide, 1-acetyl- (4 - { 3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] benzoyl.} Piperazine, 3-chloro-N- (2-dimethylamino) ethyl-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] benzamide, 3-chloro-4- [4-methyl- 5- (1-Phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] -N- (2-morpholin-4-yl) ethylbenzamide, 4- [4-methyl-5- (1-phenylcyclopropyl) ) -4H- [1,2, 4] triazol-3-yl] -3-methoxybenzamide, 3-chloro-4-. {4-methyl-5- [1- (4-fluorophenyl) cyclopropyl] -4H- [1,2, 4] triazol-3-yl.}. Benzamide, 3-chloro-N-methyl-4-. { . 4-methyl-5- [1- (4-fluorophenyl) - cyclopropyl] -4H- [1,2, 4] triazol-3-yl} benzamide, 4- [4-isopropyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzamide, 4-. { 5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,2, 4] triazol-3-yl} benzamide, 4-chloro-3-. { 5- [1- (4-fluorophenyl) cyclopropyl] -4-methyl-4H- [1,2, 4] triazol-3-yl} benzamide, 4-chloro-3-. { 5- [1-phenylcyclopropyl] -4-methyl-4H- [1,2, 4] triazol-3-yl} benzamide, 3-chloro-4- [4-ethyl-5- (1-phenylcyclopropyl) -4 H- [1, 2, 4] triazol-3-yl] benzamide, 3-chloro-4. { 4-ethyl-5- [1- (4-fluorophenyl) cyclopropyl] -4H- [1,2,4] triazol-3-yl} benzamide, 3- [4-isopropyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] -triazol-3-yl] benzamide, 3-. { 5- [1- (4-Fluoro-phenyl) -cyclopropyl] -4-isopropyl-4H- [1,2, 4] triazol-3-yl} benzamide, N-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] phenyl} -l-morpholinecarboxamide, 3-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] -phenyl} -l, 1-dimethylurea,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,] triazol-3-yl] -phenyl} urea, N-. { 3-Chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4 H- [1, 2,4] triazol-3-yl] -phenyl} ethyl carbamate, N- [3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} -l- (4-methoxypiperidine) -carboxamide, N-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} -l- (3-hydroxypiperidine) -carboxamide, N-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] phenyl} -l- (4-hydroxypiperidine) -carboxamide, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] -phenyl} -3-methoxyurea, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} -3-hydroxy-3-methylurea, 1- (3-chloro-4-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-methyl-4H- [1, 2,4] triazole-3 -yl.}. phenyl) -3-methoxyurea, 1- (4-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,4] triazole-3- il.}. phenyl) -3-methoxyurea, 1- (3. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,2,4] triazol-3-yl .}. phenyl) -3-methoxyurea, 3-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -phenyl} oxazolidin-2-one, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} Imidazolidin-2-one, 3- (3-chloro-4-5- [1- (4-fluoro-phenyl) -cyclopropyl] -4-methyl-4H- [1,2,4] triazol-3-yl} phenyl) oxazolidin-2-one, 3- (4-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1, 2,4] triazol-3-yl. phenyl) oxazolidin-2-one, 3- (4-chloro-3-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-methyl-4H- [1,2,4] triazole- 3-yl.} Phenyl) oxazolidin-2-one, 3- (3. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,2,4] triazole- 3-yl.} Phenyl) oxazolidin-2-one, N- (4-chloro-3-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-methyl-4H- [1,2, 4] triazol-3-yl.}. Phenyl) carbamate, a prodrug thereof or a pharmaceutically acceptable salt thereof.

15. The triazole compound according to claim 1, which is 3-chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4H- [1,2,4] triazole-3. -yl] -benzamide,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] triazol-3-yl] benzoyl} morpholine, 3-chloro-N-methyl-4- [4-methyl-5- (1-phenyl-cyclo-propyl) -4H- [1,2, 4] triazol-3-yl] -benzamide, 3-chloro-N, N-dimethyl-4- [4-methyl-5- (1-phenyl-cyclo-propyl) -4H- [1,2, 4] triazol-3-yl] -benzamide, 3-chloro-N- (2-hydroxy-ethyl) ) -4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2,4] triazol-3-yl] -benzamide, 3-chloro-N-isopropyl-4- [4-methyl- 5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] benzamide,. { 3-Chloro-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzoyl} piperidine,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzoyl} - (4-hydroxy) piperidine, N-carbamoylmethyl-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] benzamide, 3- chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] -N- (2,2,2-trifluoroethyl) -benzamide, N- ( 2-acetylamino) ethyl-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2, 4] triazol-3-yl] benzamide, 3-chloro-N- (2 -methoxy) ethyl-4- [4-methyl-5- (1-phenyl-cyclopropyl) -4 H- [1, 2, 4] triazol-3-yl] benzamide, 1-acetyl- (4-. {3 -chloro-4- [4-methyl-5- (1-phenyl-cyclo-propyl) -4H- [1, 2, 4] triazol-3-yl] benzoyl.} piperazine, 3-chloro-N- (2- dimethylamino) ethyl-4- [4-methyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] benzamide, 3-chloro-4- [4-methyl-5- ( 1-Phenylcyclopropyl) -4H- [1,2,4] triazol-3-yl] -N- (2-morpholin-4-yl) -ethylbenzamide, 4- [4-methyl-5- (1-phenylcyclopropyl) - 4H- [1,2, 4] triazol-3-yl] -3-methoxybenzamide, 3-chloro-4-. {4-methyl-5- [1- (4-fluorophenyl) cyclopropyl] -4H- [1 , 2,4] triazol-3-yl.} Benzamide, 3-chloro-N-methyl-4-. {4 -methyl-5- [1- (4-fluorophenyl) -cyclopropyl] -4H- [1,2, 4] triazol-3-yl} benzamide, 4- [4-isopropyl-5- (1-phenylcyclopropyl) -4H- [1,2,4] -triazol-3-yl] benzamide, 4-. { 5- [1- (4-fluorophenyl) -cyclopropyl] -4-isopropyl-4H- [1, 2, 4] triazol-3-yl} benzamide, 4-chloro-3-. { 5- [1- (4-fluorophenyl) -cyclopropyl] -4-methyl-4H- [1, 2,4] triazol-3-yl} benzamide, 4-chloro-3-. { 5- [1-Phenylcyclopropyl] -4-methyl-4H- [1,2,4] triazol-3-yl} benzamide, 3-chloro-4- [4-ethyl-5- (1-phenylcyclopropyl) -4H- [1,2, 4] triazol-3-yl] benzamide, 3-chloro-4-. { 4-ethyl-5- [1- (4-fluorophenyl) cyclopropyl] -4H- [1,2, 4] triazol-3-yl} benzamide, 3- [4-isopropyl-5- (1-phenylcyclopropyl) -4 H- [1,2,4] -triazol-3-yl] benzamide, 3-. { 5- [1- (4-fluorophenyl) -cyclopropyl] -4-isopropyl-4H- [1,2,4] triazol-3-yl} benzamide, a prodrug thereof or a pharmaceutically acceptable salt thereof.

16. The triazole compound according to claim 1, which is N-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} -l-morpholinecarboxamide, 3-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -phenyl} -l, 1-dimethylurea,. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -phenyl} urea, N-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] phenyl} -! - (4-methoxypiperidine) -carboxamide, N-3-chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -phenyl} -l- (3-hydroxypiperidin) - -carboxamide, N-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] -phenyl} -l- (4-hydroxypiperidine) -carboxamide, 1-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] -phenyl} -3-methoxyurea, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] phenyl} -3-hydroxy-3-methylurea, 1- (3-chloro-4-. {5- [1- (4-fluorophenyl) -cyclopropyl] -4-methyl-4H- [1,2,4] triazole- 3-yl.}.-Phenyl) -3-methoxyurea, 1- (4-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,2,4] triazole- 3-yl.}.-Phenyl) -3-methoxyurea, 1- (3. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1, 2,4] triazole- 3-yl.}.-Phenyl) -3-methoxyurea, a prodrug thereof or a pharmaceutically acceptable salt thereof.

17. The triazole compound according to claim 1, which is 3-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1, 2,4] triazol-3-yl] -phenyl} oxazolidin-2-one, l-. { 3-Chloro-4- [4-methyl-5- (1-phenylcyclopropyl) -4 H- [1,2, 4] triazol-3-yl] phenyl} imidazolidin-2-one, 3- (3-chloro-4-. {5- [1- (4-fluoro-phenyl) -cyclopropyl] -4-methyl-4H- [1,2,4] triazole-3- il.} phenyl) oxazolidin-2-one, 3- (4-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1,2,4] triazole-3- il.} phenyl) oxazolidin-2-one, 3- (4-chloro-3-. {5- [1- (4-fluorophenyl) cyclopropyl] -4-methyl-4H- [1,2,4] triazol-3-yl.} phenyl) oxazolidin-2-one, 3- (3. {5- [1- (4-fluorophenyl) cyclopropyl] -4-isopropyl-4H- [1, 2, 4] triazol-3-yl.} phenyl) oxazolidin-2-one, a prodrug thereof or a pharmaceutically acceptable salt thereof.

18. A pharmaceutical composition comprising the triazole compound according to any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

19. An inhibitor of HSDl (11-beta-hydroxysteroid dehydrogenase 1) comprising the triazole compound according to any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

20. A therapeutic or prophylactic drug for diabetes, which comprises the triazole compound according to any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

21. A therapeutic or prophylactic drug for obesity, which comprises the triazole compound according to any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

22. A therapeutic or prophylactic drug for metabolic syndrome, which comprises the triazole compound according to any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof as an effective component.

23.- A method for the treatment or prophylaxis of diabetes, which comprises administering an effective amount of the triazole compound according to any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

24. A method for the treatment or prophylaxis of obesity, which comprises administering an effective amount of the triazole compound according to any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

25. A method for the treatment or prophylaxis of metabolic syndrome, which comprises administering an effective amount of the triazole compound according to any of claims 1 to 17, a prodrug thereof or a pharmaceutically acceptable salt thereof to a mammal.

26. The method according to claim 23, characterized in that a different therapeutic drug for diabetes is used in combination.

27. The method according to claim 26, characterized in that the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of a preparation of insulin, a sulphonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an a-glucosidase inhibitor and an insulin sensitizer.

28. The method according to claim 27, characterized in that the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glibuzol, metformin hydrochloride, buformin hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.

29. The method according to claim 24, characterized in that a different therapeutic drug for diabetes is used in combination.

30. The method according to claim 29, characterized in that the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of an insulin preparation, a sulphonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an a-glucosidase inhibitor and an insulin sensitizer.

31. The method according to claim 30, characterized in that the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glibuzol, metformin hydrochloride, buformin hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.

32. The method according to claim 25, characterized in that a different therapeutic drug for diabetes is used in combination.

33. The method according to claim 32, characterized in that the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of an insulin preparation, a sulphonylurea, an insulin secretagogue, a sulfonamide, a biguanide, an a-glucosidase inhibitor and an insulin sensitizer.

34. The method according to claim 33, characterized in that the different therapeutic drug for diabetes is one or more pharmaceutical agents that are selected from the group consisting of insulin, glibenclamide, tolbutamide, glyclopyramide, acetohexamide, glimepiride, tolazamide, gliclazide, nateglinide, glibuzol, metformin hydrochloride, buformin hydrochloride, voglibose, acarbose and pioglitazone hydrochloride.

35. The method according to claim 23, characterized in that a different therapeutic drug for obesity is used in combination.

36. The method according to claim 35, characterized in that the different therapeutic drug for obesity is Mazindol.

37. The method according to claim 24, characterized in that a different therapeutic drug for obesity is used in combination.

38. - The method according to claim 37, characterized in that the different therapeutic drug for obesity is Mazindol.

39.- The method according to claim 25, characterized in that a different therapeutic drug is used for obesity in combination.

40. The method according to claim 39, characterized in that the different therapeutic drug for obesity is Mazindol.